FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz’s Filgrastim Faces Naming and Court Hurdles

Lignende værker

• Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA
  af: Awad, Mina, et al.
  Udgivet: (2017)
• Conflicting Opinions Flood FDA on Its Proposal for Biosimilar Naming
  af: Barlas, Stephen
  Udgivet: (2016)
• FDA Pleases No One With Final Guidance On Naming of Biologicals and Biosimilars
  af: Barlas, Stephen
  Udgivet: (2017)
• Early Biosimilars Face Hurdles to Acceptance: The FDA Has Approved Few, So Lack of Competition Is Keeping Prices High
  af: Barlas, Stephen
  Udgivet: (2016)
• FDA and EMA Biosimilar Approvals
  af: Jung, Emily H., et al.
  Udgivet: (2019)